AB1659 MOROCCAN SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER IN RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS (RBSMR): 3 YEAR-FOLLOW UP ANALYSIS
Authors: I. Hmamouchi, N. EL Ouardi, R. Abouqal, F. Allali, R. Bahiri, A. Bezza, I. El Bouchti, I. El Ghozlani, T. Harzy, H. Hassikou, I. Linda, S. Janani, R. Niamane, A. EL Maghraoui
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Limited data have been published on tolerance and efficacy of biotherapy in moroccan patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). <h3>Objectives</h3> To assess in real life the safety and efficacy of biological treatments in moroccan patients with RA and SpA. <h3>Methods</h3> The RBSMR is a registry of biological therapies in rheumatic diseases from the Moroccan Society of Rheumatology. The patients recruited were over the age of 18 years, diagnosed with RA or SpA, fulfilled ACR/EULAR 2010 criteria and ASAS 2009 criteria respectively and treated with biologics (initiation or ongoing biotherapy) in 10 Moroccan university medical centers. The inclusion period was from May 2017 to January 2019. Follow-up data were collected every 6 months for 3 years. The details of the data collected have been published previously. [1] Statistical analysis was performed using Jamovi software, 1.6. <h3>Results</h3> A total of 225 RA and 194 SpA including 170 ankylosing spondylitis were treated with biologics (bDMARDs). Overall median age at inclusion was 53 and 39 years. The median disease duration was 146 and 131 months for RA and SpA respectively.163 (72.4%) RA and 137(70.6%) SpA received a first line bDMARDs.10.7 % RA and 55.2 % SpA were prescribed bDMARDs in combination with csDMARDs. After 3 years of follow-up, median DAS28 CRP was 2.6 [0.9-4] (p&lt;0.001) and median ASDAS CRP was 1.8 [1-2.4] (p=0.66). The most commonly used drug was rituximab (60%) in RA and etanercept (33%) in SpA. At 3 years-follow up, 18.3% and 17.4% adverse events were reported in RA and SpA patients respectively. The most common adverse events reported in RA and SpA were infections, mainly nonspecific infections, in both diseases (5.8%, 5.2%). One lymph node tuberculosis in an RA patient taking infliximab and 6 cases of tuberculosis in SpA patients taking anti-TNFs were reported in our registry. Malignancy was observed in 3 patients with RA (1 non-Hodgkin lymphoma, 1 bladder cancer and 1 breast cancer) and 2 SpA patients (1 vocal cord carcinoma and 1 multiple myeloma). During follow-up, 38bDMARDs switchers were reported in RA patients (10 at 1 year, 9 at 2 years and 9 at 3 years), while 41 switchers were reported in SpA patients (23 at 1 year, 14 at 2 years and 4 at 3 years). <h3>Conclusion</h3> In this real-world analysis of data from the RBSMR registry, a considerable proportion of patients with RA and Spa had an adequate response to bDMARDs at 36 months. Infections, mainly nonspecific infections, were the main adverse events in both RA and SpA of our registry. <h3>Reference</h3> [1]Hmamouchi I et al. The Moroccan registry of biological therapies in rheumatic diseases (RBSMR): methods and preliminaries results. Rev Mar Rhum 2019;49:32-7 <h3>Acknowledgements</h3> The authors would like to thank the Scientific Committee and national principal investigators of the RBSMR study, Drs Redouane Abouqal, Lahcen Achemlal, Fadoua Allali, Rachid Bahiri, Ahmed Bezza, Imane El Bouchti, Imad El Ghozlani, Abellah El Maghraoui, Toufik Harzy, Ihsane Hmamouchi, Linda Ichchou, Ouafa Mkinsi, Kawtar Nassar, Saadia Janani, and Redouane Niamane; and patients who agreed to participate in this study. <h3>Disclosure of Interests</h3> None Declared.